Moderna Shares Drop 25% After Vaccine Leak

Moderna shares fell 25% after leaked data for its personalized cancer vaccine intismeran autogene paired with Merck's Keytruda. Analysts say the drop reflects inflated investor expectations rather than disappointing results, as full trial data shows promising 42% recurrence reduction for melanoma patients.